stockrowKALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million.
- EPS
- +99.9%
- Free cash flow
- +80.2%
Quarter to June 2026, against a year earlier
Follow KALA
Alert me
KALA BIO, Inc. (KALA) EV/Sales
As of 6 November 2026, KALA BIO, Inc. (KALA) trades at a EV/Sales of 8.0×. Over the past ten years it has ranged from −0.8× (November 2023) to 112× (July 2020); the current reading is higher than 69% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 5.2× | (27.52%) |
| FY2021 | 7.2× | (83.43%) |
| FY2020 | 43.4× | 132.43% |
| FY2019 | 18.7× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2022 | 2.6× | (66.86%) |
| Jun 2022 | 7.7× | (39.97%) |
| Mar 2022 | 12.9× | 78.99% |
| Dec 2021 | 7.2× | (34.75%) |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.7× |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 1.5× |
| KALA KALA BIO, Inc. | 8.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)